DNase I Inhibitors
1 drugsAbout DNase I
Deoxyribonuclease I (DNase I) is an endonuclease enzyme that degrades DNA, playing a crucial role in various biological processes by cleaving DNA. Understanding its function can pave the way for developing novel therapies by manipulating DNA degradation processes.
DNase I's ability to cleave DNA is crucial in various biological processes, and understanding its role can pave the way for developing novel therapies. Currently, there is no genetic evidence data available linking DNase I to specific diseases.
DNase I is targeted by one FDA-approved drug, PULMOZYME (Roche), a biologic used in respiratory indications since 1993. Further exploration of this target could lead to new treatments beyond respiratory illnesses.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Chronic Hepatitis B with only 1 trials.
Top DNase I Drugs
Roche is the only company with an approved drug targeting DNase I.
Low competition suggests high entry barriers or limited perceived opportunity.
DNase I Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets DNase I, using enzyme modality.
The lack of modality diversity indicates whitespace opportunity for small molecules or other approaches.
DNase I Clinical Trials 21 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 1 | 1 | 0 | 50% |
| Phase 2 | 8 | 4 | 0 | 4 | 100% |
| Phase 3 | 5 | 2 | 2 | 1 | 50% |
| Phase 4 | 6 | 4 | 2 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
DNase I Drug Approval Timeline (1993 - 1993)
PULMOZYME was approved in 1993 and remains the only approved drug.
The single approval nearly 30 years ago suggests a saturated market or limited innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 22 clinical trials targeting DNase I.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities